In breast cancer, compared with normal tissues, the overexpression of LOX in breast cancer tissues was associated with tumor volume, lymph node metastasis, and poor prognosis [24]; it also can be used as an evaluation indicator of poor prognosis in patients with estrogen receptor (ER)-negative breast cancer [25]. Here, ESR1 is linked to breast cancer.